GlassScriptPhysician profile
Cira L Amenta
NPI 1770552762
$22,558.40
in general payments reported to CMS, 2019-2025
70 companies · $3,229 in 2025
The $3,229 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,119 · 2020: $2,187 · 2021: $2,918 · 2022: $3,789 · 2023: $3,604 · 2024: $3,713 · 2025: $3,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,084.08 |
| Education | $462.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,714.87 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,429.66 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $2,205.05 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $1,686.49 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $1,442.84 | 2019-2025 | |
| Astellas Pharma US INC | $1,201.92 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,036.67 | 2019-2025 | Jardiance |
| Amgen INC. | $963.85 | 2019-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $751.66 | 2019-2023 | |
| Glaxosmithkline, LLC. | $743.49 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $647.26 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $517.21 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.83 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $347.95 | 2019-2023 | Gardasil 9, Belsomra, Steglatro |
| Sunovion Pharmaceuticals INC. | $333.91 | 2019-2022 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $315.72 | 2022-2025 | Sunosi, Auvelity |
| Kowa Pharmaceuticals America, INC. | $306.11 | 2019-2025 | Zoryve, Seglentis |
| Sumitomo Pharma America, INC. | $303.86 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $298.17 | 2022-2025 | |
| Millicent US INC | $297.17 | 2024-2025 | Intrarosa, Femring |
| Otsuka America Pharmaceutical, INC. | $244.10 | 2020-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $214.26 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $213.69 | 2019-2020 | |
| Exact Sciences Corporation | $204.56 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $195.33 | 2022-2025 | Rexulti |
| Esperion Therapeutics, INC. | $191.91 | 2020-2023 | Nexletol |
| Corcept Therapeutics | $159.32 | 2022-2023 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $140.96 | 2022 | |
| Antares Pharma, INC. | $122.08 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Bausch Health US, LLC | $112.12 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $111.29 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $104.89 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.41 | 2022-2025 | Caplyta |
| Almatica Pharma LLC | $97.31 | 2021-2023 | Loreev Xr |
| Dexcom, INC. | $91.28 | 2022-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $90.74 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $86.92 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $83.21 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Horizon Therapeutics Plc | $78.07 | 2019-2022 | |
| Harmony Biosciences LLC | $75.42 | 2022-2023 | Wakix |
| Abbott Laboratories | $74.38 | 2021-2023 | Freestyle Libre 3 |
| Eisai INC. | $67.87 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $55.22 | 2020-2021 | |
| Genentech USA, INC. | $48.98 | 2019-2021 | |
| Ardelyx, INC. | $45.12 | 2024 | Ibsrela |
| Amneal Pharmaceuticals LLC | $43.32 | 2019-2021 | |
| Ibsa Pharma INC. | $39.26 | 2019-2021 | |
| Tersera Therapeutics LLC | $38.16 | 2019 | |
| Alfasigma USA, INC. | $35.44 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.28 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $34.27 | 2024 | Ultomiris |
| Bardy Diagnostics, INC. | $30.00 | 2022 | |
| Exeltis, USA INC. | $29.51 | 2021 | |
| Sanofi Pasteur INC. | $27.67 | 2019-2020 | |
| Radius Health, INC. | $27.22 | 2019 | |
| Halozyme INC | $24.86 | 2023 | |
| Circassia INC. | $24.79 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.36 | 2024 | |
| Hikma Pharmaceuticals USA | $24.08 | 2019 | |
| Therapeuticsmd, INC. | $21.77 | 2019 | |
| Aimmune Therapeutics, INC. | $21.67 | 2025 | Zenpep |
| Tolmar, INC. | $19.00 | 2023 | |
| Inspire Medical Systems, INC. | $18.83 | 2025 | Inspire |
| Phadia US INC. | $17.50 | 2020 | |
| Endogastric Solutions, INC | $16.97 | 2024 | Esophyx |
| Cequr Corporation | $14.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Medicure Pharma INC. | $14.65 | 2021 | |
| Baxter Healthcare | $14.32 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Vistapharm, INC. | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cira Amenta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.